Anthony N. Imudia

Anthony N. Imudia

Auto-generated profile, based on publicly available information

Anthony N. Imudia

Morsani College of Medicine, Department of Obstetrics and Gynecology, University of South Florida, Tampa, USA

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2015 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Closed access
EMEmad Mikhail
Emad Mikhail
Jason Lee SalemiJason Lee Salemi
Jason Lee Salemi
MMMulubrhan F. Mogos
Mulubrhan F. Mogos
SHStuart Hart
Stuart Hart
HSHamisu M. Salihu
Hamisu M. Salihu
AIAnthony N. Imudia
Anthony N. Imudia

16 August 2011 in The Journal of Maternal-Fetal & Neonatal Medicine
Verified
Journal Article
Closed access
LFLusia C. Filetti
Lusia C. Filetti
AIAnthony N. Imudia
Anthony N. Imudia
ZAZain Al-Safi
Zain Al-Safi
DHDeslyn T. Hobson
Deslyn T. Hobson
AAAwoniyi Olumide Awonuga
Awoniyi Olumide Awonuga
RBRay O. Bahado-Singh
Ray O. Bahado-Singh
Objective: Delayed postpartum preeclampsia is a poorly studied disorder. We compared new onset delayed postpartum preeclampsia (NOPP) to recurrent/persistent, delayed onset postpartum preeclampsia (RPP) to see whether these were different disorders. Methods: Delayed onset preeclampsia was defined as readmission >2 days to ≤6 weeks postpartum for preeclampsia. The NOPP group had no antecedent diagnosis of hypertensive disorders in the current pregnancy, and was compared to the RPP defined as a prior hypertensive disorder in the current pregnancy in terms of maternal demographics, obstetric and medical history, intrapartum and early postpartum course and clinical signs and symptoms and outcomes on postpartum readmission. Results: There were a total of 56 (36.8%) patients in the RPP and 96 (63.2%) patients in the NOPP groups. NOPP cases delivered significantly later 39.0 ± 2 weeks vs. 37 ± 3.0 weeks p < 0.001, and had significantly lower blood pressure during the antepartum, early postpartum and readmission periods. In addition the NOPP group had significantly higher average number of symptoms 2 vs. 1.5 p = 0.013 on postpartum readmission. There were no statistically significant differences in the rates of major complications. Conclusions: In this comprehensive study of delayed postpartum preeclampsia, there were few significant differences in the clinical course and no differences in complications in the NOPP subgroup compared to cases with preeclampsia recurring in the late postpartum period.

6 August 2021 in Systems Biology in Reproductive Medicine
Verified
Journal Article
Closed access
PSPapri Sarkar
Papri Sarkar
SJSangita Jindal
Sangita Jindal
ENErika P. New
Erika P. New
RSRachel G. Sprague
Rachel G. Sprague
JTJean Tanner
Jean Tanner
AIAnthony N. Imudia
Anthony N. Imudia
Preimplantation genetic testing for aneuploidy is associated with increased pregnancy success and reduced miscarriage in women 35 years and older when embryos are available for transfer. In this retrospective cohort study our objective was to evaluate if this holds true in good prognosis patients and across all age groups. Data were obtained from the Society for Assisted Reproductive Technology between 2014–2015. We included only the first single frozen embryo transfer where indication for corresponding ‘stimulation/freeze-all cycle’ was for reducing risk of ovarian hyperstimulation syndrome and performance of PGT-A for selecting euploid embryos. Our main outcomes were live birth and miscarriage rates. Among 37 year old, no difference was observed between non-PGT-A tested and tested groups in LBR (48.1% vs. 53.2%, aOR 1.27, 95% CI 0.8–2.02) and miscarriage rates (6.2% vs. 8.5%, aOR1.34, 95% CI 0.52–3.43). To conclude, PGT-A tested embryos did not improve LBR and miscarriage rates in a good prognosis IVF population across all age groups. Abbreviations: PGT-A: preimplantation genetic testing for aneuploidy; FET: frozen embryo transfer; LBR: live birth rate; OHSS: ovarian hyperstimulation syndrome; SART: society for assisted reproductive technology

16 May 2022 in Journal of Women's Health
Verified
Journal Article
Open access
ESElizabeth A. Stewart
Elizabeth A. Stewart
DADavid F. Archer
David F. Archer
COCharlotte D. Owens
Charlotte D. Owens
KBKurt T. Barnhart
Kurt T. Barnhart
DBDAVID BRADLEY
DAVID BRADLEY
AAAyman Al-Hendy
Ayman Al-Hendy
Objective: To assess outcomes of women with uterine fibroids (UFs) and heavy menstrual bleeding (HMB) treated with 300 mg elagolix twice daily plus add-back therapy (E2 1 mg/NETA 0.5 mg once daily) or placebo who were not considered responders in pooled analysis of two phase 3, 6-month randomized clinical trials (Elaris UF-1 and UF-2). Methods: Responders were defined as women who met both primary end point bleeding criteria (<80 mL menstrual blood loss [MBL] during the final month and ≥50% reduction in MBL from baseline to the final month) and either completed the study or discontinued due to predefined reasons. Thus, women termed nonresponders who were analyzed in this study who met neither or one bleeding end point or met both criteria but prematurely discontinued treatment because of adverse events, perceived lack of efficacy, or required surgical or interventional treatment for UFs were analyzed in this study. This post hoc analysis assessed mean changes from baseline in MBL, as well as adverse events. Results: Among 367 women receiving elagolix with add-back with observed data, 89 (24%) were not considered responders. Within this subset, 17 (19%) women met both bleeding criteria but prematurely discontinued treatment for the reasons mentioned above, while 23 (26%) met one bleeding criterion and 49 (55%) met neither bleeding criteria, regardless of discontinuation status. Among all nonresponders, a numerical trend toward greater mean reductions in MBL was observed in those receiving elagolix with add-back, compared with placebo group nonresponders. No differences in adverse events were observed between responders and nonresponders. Conclusion: Forty of 89 (45%) women with HMB and UFs who were classified as nonresponders in the UF-1 or UF-2 trials may have had a clinically meaningful response to elagolix with add-back therapy because they met at least one of the objective bleeding criteria. Clinical Trial Registration: Clinicaltrials.gov, NCT02654054 and NCT02691494. (NEJM 2020; 382:328–340) DOI: 10.1056/NEJMoa1904351

2 December 2020 in Journal of Obstetrics and Gynaecology
Verified
Journal Article
Closed access
ENErika P. New
Erika P. New
PSPapri Sarkar
Papri Sarkar
EMEmad Mikhail
Emad Mikhail
SPShayne Plosker
Shayne Plosker
AIAnthony N. Imudia
Anthony N. Imudia
A pre-post interventional study of patients undergoing office hysteroscopy alone and in combination with endometrial biopsy was performed during October 2015–March 2018 to evaluate the effect of low dose vaginal misoprostol on patient’s pain. Pain scores were assessed using the visual analog scale at the completion of the procedure. There were 646 patients included in the study. Of these, 462 had office hysteroscopy alone; 206 (44.6%) received 50 mcg of vaginal misoprostol the night prior to the procedure and the remaining 256 (55.4%) patients had no cervical ripening. The reported pain score following hysteroscopy was significantly lower among patients who received misoprostol [4(0–10) vs. 5(0–10); p=.001]. Most patients (78.2%) did not report any misoprostol related side effects. Of the 184 patients who underwent a combination of office hysteroscopy and endometrial biopsy, 97 (52.7%) received pre-procedure vaginal misoprostol while 87 (47.3%) did not. Post procedure pain was independent of pre-treatment with vaginal misoprostol (6.3 ± 2.7 vs. 6.6 ± 2.7; p = .54).

7 September 2025 in Journal of Assisted Reproduction and Genetics
Verified
Journal Article
Closed access
PDF file
CMCarrie A. Malcom
Carrie A. Malcom
KFKerry Flannagan
Kerry Flannagan
PRPhillip A. Romanski
Phillip A. Romanski
AIAnthony N. Imudia
Anthony N. Imudia